EBR's Principal Activity is the medical device company focussed on developing and bringing to market, devices to treat patients with certain types of heart failure.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-60.59%|
EBR Systems Inc (EBR) is a United States based company dedicated to treatment of cardiac rhythm disease by providing physiologically effective stimulation through cardiac pacing. The Company's patented Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the source of complications and reliability issues in cardiac rhythm management.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Ms Karen Ruth Drexler||Non-Executive Director||Oct 2021||
Ms Karen Ruth Drexler
Ms Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Ms Drexler serves on the boards of two other public companies, Resmed, Inc. (NYSE, ASX:RMD), where she serves on the compensation and nominating and governance committees, and Outset Medical Inc.(NASDAQ: OM), where she chairs the compensation committee and serves on the nominating and governance committee. Ms Drexler is also on the board of three private companies: Bone Health Technologies Inc., VIDA Diagnostics Inc. and Tivic Health Systems, Inc.. Ms Drexler also acts as a senior strategic advisor for other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Ms Drexler is an active mentor and advisor with Astia. She is a founding member of Astia Angels and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women's Health Councils for Springboard.
|Dr Bronwyn Joy Evans||Non-Executive Director||Oct 2021||
Dr Bronwyn Joy Evans
Dr Evans is an experienced leader and CEO with a technical background across multiple industry sectors including medical technology, manufacturing, power generation and distribution and technical regulation and standards. Dr Evans is currently the CEO of Engineers Australia, the Chair of Building4.0 CRC, and the Director at GME Pty Ltd. Prior to her role with Engineers Australia, Dr Evans was the CEO of Standards Australia. Dr Evans has previously held positions in innovation initiatives, including as Chair of MTPConnect and was a member of the Industry 4.0 Advanced Manufacturing Forum Leadership group. She has also held various senior engineering roles, including at Cochlear and GE Healthcare. She is an Honorary Fellow of the University of Wollongong and Engineers Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering. She also chairs Risk Committee.
|Dr David Mark Steinhaus||Non-Executive Director||Oct 2021||
Dr David Mark Steinhaus
Dr Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc (NYSE:MDT). Dr Steinhaus joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. His responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies and medical groups. Dr Steinhaus has been closely associated with research and academia, performing clinical studies in implantable cardiac devices and leads. He served as Chair of the Department of Cardiology, and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke's Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine, and has instructed students in medicine since 1982. Since leaving Medtronic, he has served as a consultant and board member to multiple established and early stage medical device companies. He is currently the Executive Chairman of the board of Enopace Biomedical Ltd., a company which produces therapeutic neuromodulation devices for the treatment of heart failure. He is also a member of Risk Committee.
|Mr John Graham McCutcheon||Chief Executive Officer,President,Executive Director||Jun 2019||
Mr John Graham McCutcheon
Chief Executive Officer,President,Executive Director
Mr McCutcheon has served as President and CEO of EBR since June 2019 and is responsible for the overall management and strategic direction of EBR. Mr McCutcheon has over 35 years of experience in sales, marketing, and management of medical device companies. Prior to joining EBR, Mr McCutcheon was the President and CEO of Ceterix Orthopaedics, Inc. for nine years from 2010 to 2019. He also held CEO roles at Ventus Medical, Inc. (2009-2010) and Emphasys Medical, Inc. (2000-2009).
|Dr Christopher Dean Nave||Non-Executive Director||Oct 2017||
Dr Christopher Dean Nave
Dr Nave is a founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialisation Fund. Dr Nave previously served as the Director of Commercialisation at the Baker Heart Research Institute. Dr Nave is currently a director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd, Global Kinetics Corporation Ltd, OccuRx Pty. Ltd., Osprey Medical, Inc. (ASX:OSP), PolyActiva Pty Ltd and Que Oncology, Inc. Dr Nave was also a chairperson of Fibrotech Therapeutics Pty Ltd and a director of Spinifex Pharmaceuticals, Inc. He is also a member of Risk Committee.
|Mr Trevor John Moody||Non-Executive Director||Oct 2017||
Mr Trevor John Moody
Mr Moody currently serves as Medical Device Partner at M.H. Carnegie & Co. (since October 2013), where he makes investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Mr Moody was previously a General Partner at Frazier Healthcare Ventures. Mr Moody is currently a director of electroCore, Inc. (NASDAQ: ECOR), Australian Medtech Services Pty Ltd, Cardiac Dimensions Pty Ltd, Renew Medical Pty Ltd, Serene Medical Pty Limited, The Brain Protection Company Pty Ltd, and CurvaFix, Inc. Mr Moody also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long distance travel for medical treatment. Mr Moody was a director of Simplify Medical Pty Ltd at the time of its sale to NuVasive, Inc. (NASDAQ: NUVA).
|Mr Allan Roger Will||Executive Chairman,Executive Director||May 2003||
Mr Allan Roger Will
Executive Chairman,Executive Director
Mr Will is a seasoned executive with experience founding, funding, operating, and selling medical device companies. In addition to his role with the Company, Mr Will currently serves as chair of the boards of Fractyl Health, Inc. and SetPoint Medical Corporation, and a director of Fogarty Innovation, a not-for-profit institute promoting innovation in medical technology founded by Dr Thomas J Fogarty. Mr Will was also founding Managing Director of Split Rock Partners' Silicon Valley office, focusing on therapeutic medical devices, having joined Split Rock Partners' predecessor entity St. Paul Venture Capital (SPVC) in 2002. Mr Will was founder, chair and CEO of The Foundry, co-founding 11 companies there, including Ardian, Evalve, Inc. and Concentric Medical Inc. Mr Will is an inventor on more than 30 issued patents, is a University of Maryland Distinguished Alumnus and a recipient of the ASTIA/Deloitte Excellence in Mentoring Women Executives Award. He served on the MIT Entrepreneurship Center Shareholders' Board and the University of Maryland President's Committee on Innovation and Entrepreneurship.
|Mr Brendan Case||Company Secretary||N/A|
The current holdings of EBR directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
No Substantial Shareholders for EBR in our database.
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.